{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:29:38Z","timestamp":1778048978421,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To compare efficacy and tolerability of solifenacin 5\u2009mg\/day versus other oral antimuscarinic agents for the treatment of overactive bladder (OAB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literature searches of MEDLINE, Embase, and the Cochrane Library were undertaken to identify randomized controlled trials in OAB (2000\u20102015) for antimuscarinic agents. A network meta\u2010analysis (NMA) was performed to estimate efficacy and tolerability outcomes for solifenacin 5\u2009mg\/day relative to other antimuscarinics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The NMA included 53 eligible trials (published, <jats:italic>n<\/jats:italic>\u2009=\u200948; unpublished on search date, <jats:italic>n<\/jats:italic>\u2009=\u20095). Solifenacin 5\u2009mg\/day was significantly more effective than tolterodine 4\u2009mg\/day for reducing incontinence and urgency urinary incontinence (UUI) episodes, but significantly less effective than solifenacin 10\u2009mg\/day for micturition; no other statistically significant differences were noted for efficacy. Solifenacin 5\u2009mg\/day had a statistically significant lower risk of dry mouth compared with darifenacin 15\u2009mg\/day, fesoterodine 8\u2009mg\/day, oxybutynin extended\u2010release 10\u2009mg\/day, oxybutynin immediate\u2010release (IR) 9\u201015\u2009mg\/day, tolterodine IR 4\u2009mg\/day, propiverine 20\u2009mg\/day, and solifenacin 10\u2009mg\/day. There were no significant differences between solifenacin 5\u2009mg\/day and other antimuscarinics for risk of blurred vision, or for 11 of 17 active comparators for risk of constipation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This NMA suggests that the efficacy of solifenacin 5\u2009mg\/day is at least similar to other common antimuscarinics across the spectrum of OAB symptoms analyzed, and is more effective than tolterodine 4\u2009mg\/day in reducing incontinence and UUI episodes. Solifenacin 5\u2009mg\/day has a lower risk of dry mouth compared with several agents.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.23413","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T13:56:36Z","timestamp":1510754196000},"page":"986-996","source":"Crossref","is-referenced-by-count":13,"title":["Comparative efficacy and tolerability of solifenacin 5\u2009mg\/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta\u2010analysis"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-2502","authenticated-orcid":false,"given":"Jameel","family":"Nazir","sequence":"first","affiliation":[{"name":"Astellas Pharma Europe Ltd. Chertsey Surrey United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Con","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Guy's and St. Thomas\u2019 NHS Foundation Trust London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Aball\u00e9a","sequence":"additional","affiliation":[{"name":"Creativ\u2010Ceutical SARL St\u2010Honor\u00e9 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Maman","sequence":"additional","affiliation":[{"name":"Creativ\u2010Ceutical Ltd. London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-8599","authenticated-orcid":false,"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colette","family":"Mankowski","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd. Chertsey Surrey United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Odeyemi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd. Chertsey Surrey United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09993.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_9_4_1","volume-title":"Incontinence","author":"Abrams P","year":"2013"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1348\/135910707X187786"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.087"},{"key":"e_1_2_9_7_1","unstructured":"LucasMG BedretdinovaD BerghmansLC et al. Guidelines on urinary incontinence 2015. European Association of Urology. Available online at:http:\/\/uroweb.org\/wp\u2010content\/uploads\/EAU\u2010Guidelines\u2010Urinary\u2010Incontinence\u20102015.pdfAccessed 31 August 2016."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02626.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-016-1277-0"},{"key":"e_1_2_9_10_1","unstructured":"National Institute for Health and Care Excellence (NICE). Urinary incontinence: the management of urinary incontinence in women. 2013. Available online at:http:\/\/www.nice.org.uk\/guidance\/CG171Accessed 31 August 2016."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7387.472"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_2_9_13_1","volume-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0","author":"Higgins JPT"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.02.024"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.030"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22808"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13882"},{"key":"e_1_2_9_20_1","first-page":"92","article-title":"Concomitant medications and possible side effects of antimuscarinic agents","volume":"10","author":"MacDiarmid SA","year":"2008","journal-title":"Rev Urol"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010983"},{"key":"e_1_2_9_22_1","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"1","author":"Madhuvrata P","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3098"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11023.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07769.x"},{"key":"e_1_2_9_26_1","first-page":"S139","article-title":"Prescribing antimuscarinics for overactive bladder: how many changes do we have to get it right","volume":"21","author":"Basra R","year":"2010","journal-title":"Int Urogynecol J"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/820816"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-011-1641-7"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.080"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-55"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.060"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.010"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.23413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.23413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:08:49Z","timestamp":1695571729000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.23413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/nau.23413"],"URL":"https:\/\/doi.org\/10.1002\/nau.23413","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}